RecruitingRecruiting
Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis
NCT06865105 · AbbVie
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
A Phase 2 Multicenter, Randomized, Platform Study of Targeted Therapies for the Treatment of Adult Subjects With Active Psoriatic Arthritis
About this study
Psoriatic arthritis (PsA) is a type of arthritis that happens when the body's immune system attacks healthy cells and tissues causing joint pain, stiffness, and swelling. Symptoms can get worse and go away for periods of time. This study will evaluate the efficacy and safety of targeted therapies through a series of substudies, for the treatment of active psoriatic arthritis and to assess the changes in disease symptoms.
The therapies being assessed in this study are risankizumab, lutikizumab, ABBV-701, and ABBV-547. In Substudy 1, participants will be randomized in a 1:1:1 ratio to one of the three treatment arms: lutikizumab monotherapy, risankizumab monotherapy or a combination therapy of lutikizumab and risankizumab. In Substudy 2, participants will be randomized in a 1:1:1 ratio to one of the three treatment arms: ABBV-701 monotherapy, risankizumab monotherapy, or a combination therapy of ABBV-701 and risankizumab. In Substudy 3, participants will be randomized in a 1:1:1 ratio to one of three doses of ABBV-547. Around 300 participants will be enrolled in the study at approximately 110 sites worldwide.
Eligibility criteria
Inclusion Criteria:
* Participant is willing and able to comply with procedures required in the Master Protocol and relevant, actively enrolling substudies.
* Participant has a documented clinical diagnosis of PsA with symptom onset at least 6 months prior to the Screening Visit and fulfillment of the Classification Criteria for Psoriatic Arthritis (CASPAR) at Screening Visit.
* Participant has active disease defined as greater than or equal to 3 tender joints (based on 68 joint count) and greater than or equal to 3 swollen joints (based on 66 joint count) at both the Screening Visit and Baseline Visit.
* Participant has active plaque PsO, with at least one psoriatic plaque of \>= 2 cm diameter or nail changes consistent with PsO at Screening Visit.
* Participant must demonstrate intolerance or inadequate response to 1 to 2 targeted therapies (biologic or targeted synthetic disease-modifying antirheumatic drugs) approved for the treatment of PsA
Exclusion Criteria:
* Participants who have had major surgery performed within 12 weeks prior to randomization or plan to have a major surgery during conduct of the study (e.g., aneurysm removal, stomach ligation).
* Participants with the following active, chronic, or recurring infections: Are infected with human immunodeficiency virus (HIV), active hepatitis B virus (HBV) or hepatitis C virus(HCV) infection, active tuberculosis(TB)
* Active skin disease other than psoriasis (PsO) which could interfere with the assessment of PsO.
* History of fibromyalgia, any arthritis with onset prior to age 17 years, or current diagnosis of inflammatory joint disease other than psoriatic arthritis (PsA) (including but not limited to rheumatoid arthritis, gout, overlap connective tissue diseases, scleroderma, polymyositis, dermatomyositis, systemic lupus erythematosus).
Study design
Enrollment target: 300 participants
Allocation: randomized
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2025-04-11
Estimated completion: 2029-08
Last updated: 2026-11-09
Interventions
Drug: LutikizumabDrug: RisankizumabDrug: ABBV-701Drug: ABBV-547
Primary outcomes
- • Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response (At Week 16)
- • Number of Participants With Adverse Events (AEs) (Up to Week 52)
Sponsor
AbbVie · industry
Contacts & investigators
ContactABBVIE CALL CENTER · contact · abbvieclinicaltrials@abbvie.com · 844-663-3742
InvestigatorABBVIE INC. · study_director, AbbVie
All locations (41)
Newport Huntington Medical Group /ID# 272764Recruiting
Huntington Beach, California, United States
Highlands Advanced Rheumatology And Arthritis Center - Avon Park /ID# 273085Recruiting
Avon Park, Florida, United States
Clinical Research Of West Florida - Phase I Unit /ID# 273198Recruiting
Clearwater, Florida, United States
HMD Research LLC /ID# 273086Recruiting
Orlando, Florida, United States
West Broward Rheumatology Associates /ID# 272892Recruiting
Tamarac, Florida, United States
Clinical Research Of West Florida - Tampa - North Howard Avenue /ID# 273199Recruiting
Tampa, Florida, United States
Northwestern Medicine - Northwestern Memorial Hospital /ID# 275469Recruiting
Chicago, Illinois, United States
Clinic Of Dr. Robert Hozman/Clinical Investigation Specialists, Inc /ID# 272879Completed
Skokie, Illinois, United States
Willow Rheumatology and Wellness /ID# 277354Recruiting
Willowbrook, Illinois, United States
Klein & Associates /ID# 272829Completed
Cumberland, Maryland, United States
Dartmouth-Hitchcock Medical Center /ID# 272702Recruiting
Lebanon, New Hampshire, United States
Paramount Medical Research and Consulting /ID# 272757Recruiting
Middleburg Heights, Ohio, United States
Altoona Center For Clinical Research /ID# 272593Recruiting
Duncansville, Pennsylvania, United States
Private Practice - Dr. Ramesh C. Gupta /ID# 272897Recruiting
Memphis, Tennessee, United States
Tekton Research - West Gate /ID# 272765Recruiting
Austin, Texas, United States
Arthritis and Rheumatology Research Institute - Frisco /ID# 277306Recruiting
Frisco, Texas, United States
Accurate Clinical Research - Houston /ID# 272754Recruiting
Houston, Texas, United States
Tekton Research, LLC /ID# 272901Recruiting
San Antonio, Texas, United States
DM Clinical Research - Tomball /ID# 272760Recruiting
Tomball, Texas, United States
Centre Hospitalier Universite De Sherbrooke - Hotel-Dieu Hospital /ID# 273715Recruiting
Sherbrooke, Quebec, Canada
Centre de Recherche Musculo-Squelettique /ID# 274397Recruiting
Trois-Rivières, Quebec, Canada
Dr. Latha Naik Medical Professional Corporation /ID# 272803Recruiting
Saskatoon, Saskatchewan, Canada
Revmatologie /ID# 272367Recruiting
Brno, Brno-mesto, Czechia
L.K.N. Arthrocentrum /ID# 272366Recruiting
Hlučín, Moravian-Silesian Region, Czechia
Medical Plus Research /ID# 272363Recruiting
Uherské Hradiště, Czechia
PV Medical Services /ID# 272368Recruiting
Zlín, Czechia
Centre Hospitalier Universitaire de Nice - Hopital Pasteur /ID# 272771Recruiting
Nice, Alpes-Maritimes, France
Infirmerie Protestante De Lyon /ID# 273731Recruiting
Caluire-et-Cuire, Auvergne-Rhône-Alpes, France
Centre Hospitalier Regional Universitaire De Tours - Hopital Trousseau /ID# 272762Recruiting
Chambray-lès-Tours, Indre-et-Loire, France
Centre Hospitalier Regional d Orleans - Hopital de la Source /ID# 272877Completed
Orléans, Loiret, France
Chu Bordeaux - Hopital Pellegrin /ID# 273390Completed
Bordeaux, New Aquitaine, France
Borsod-Abauj-Zemplen Varmegyei Kozponti Korhaz es Egyetemi Oktatokorhaz /ID# 272572Recruiting
Miskolc, Borsod-Abauj Zemplen county, Hungary
Complex Rendelo Med Zrt. /ID# 272570Recruiting
Székesfehérvár, Fejér, Hungary
Vital-Medicina /ID# 272855Recruiting
Veszprém, Fejér, Hungary
Semmelweis Egyetem Reumatologiai es Immunologiai Klinika /ID# 273195Recruiting
Budapest, Hungary
Revita Reumatologiai Rendelo (Revita Kft.) /ID# 272857Recruiting
Budapest, Hungary
Medicover Integrated Clinical Services - Bydgoszcz (SMO/Network/Consortium) /ID# 273297Recruiting
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland
MCBK S.C. Iwona Czajkowska Anna Podrazka-Szczepaniak /ID# 273305Recruiting
Pruszków, Masovian Voivodeship, Poland
Centrum Medyczne Reuma Park /ID# 273301Recruiting
Warsaw, Masovian Voivodeship, Poland
Osteo Medic s.c. Artur Racewicz Jerzy Supronik /ID# 273304Completed
Bialystok, Podlaskie Voivodeship, Poland
Centrum Kliniczno-Badawcze J.Brzezicki, B. Gornikiewicz-Brzezicka Lekarze Spolka /ID# 273306Completed
Elblag, Warmian-Masurian Voivodeship, Poland